Rodríguez-Torres M, Burguera J, Hallman D, Rodríguez-Orengo J, Echeandia M

Idioma: Ingles.
Referencias bibliográficas: 22
Paginas: 450-463
Archivo PDF: 592.01 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Missiha S, Heathcote J, Arenovich T, Khan K. Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007; 102(10): 2181-8.

2. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, Joh T. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30(3): 787-93.

3. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley- Lucas TE, Afdhal N, Brown RS, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131(2): 470-7.

4. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350(22): 2265-71.

5. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, Rossaro L, Ankoma-Sey V, Hamzeh FM, Martin P. Peginterferon alfa- 2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009; 360(3): 257-67.

6. An Older and More Diverse Nation by Midcentury: US Census Bureau. US Census Bureau. 14-8-0008. 12-5-2011.

7. Pérez CM, Albizu C, Peña M, Torres EA, Reyes JC, Colón H, Ortiz AP, et al. Hepatitis C in Puerto Rico: a time for public health action. PR Health Sci J 2007; 26(4): 395-400.

8. Pérez CM, Marrero E, Meléndez M, Adrovet S, Colón H, Ortiz AP, Soto-Salgado M, et al. Seroepidemiology of viral hepatitis, HIV and herpes simplex type 2 in the household population aged 21-64 years in Puerto Rico. BMC Infect Dis 2010; 23(10): 76.

9. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis Crelated mortality in the United States, 1995-2004. Hepatology 2008; 47(4): 1128-35.

10. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144(10): 705-14.

11. Rodriguez-Torres M. Latinos and chronic hepatitis C: a singular population. Clin Gastroenterol Hepatol 2008; 6(5): 484-90.

12. Lepe R, Layden-Almer JE, Layden TJ, Cotler S. Ethnic differences in the presentation of chronic hepatitis C. J Viral Hepat 2006; 13(2): 116-20.

13. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, et al. Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance. Nature 2009; 461: 399-401.

14. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52(6): 1888-96.

15. Chevaliez S, Hézode C. IL28B polymorphisms and chronic hepatitis C. Gastroenterol Clin Biol 2010; 34(11): 587-9.

16. Ridruejo E, Solano A, Marciano S, Galdame O, Adrover R, Cocozzella D, Delettieres D, et al. Genetic variation in Interleukin- 28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. Ann Hepatol 2011; 10(4): 452-7.

17. Moucari R, Ripault MP, Oulès V, Martinot-Peignoux M, Asselah T, Boyer N, El Ray A, et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J Hepatol 2007; 46(4): 596-604.

18. Yu ML, Chuang WL, Dai CY, Lee LP, Hsieh MY, Lin ZY, Chen SC, et al. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. Transl Res 2006; 148(3): 120-7.

19. Reddy KR, Shiffman ML, Rodriguez-Torres M, Cheinquer H, Abdurakhmanov D, Bakulin I, Morozov V, et al. Intensified peginterferon alfa-2a/ribavirin therapy for patients with HCV genotype 1, weight ≥ 85 kg and high viral load: randomized trial. Gastroenterology 2010; 139(6): 1972-83.

20. Martinot-Peignoux M, Maylin S, Moucari R, Ripault MP, Boyer N, Cardoso AC, Giuily N, et al. Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. Antivir Ther 2009; 14(4): 501-11.

21. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55(1): 69-75.

22. Murphy AA, Herrmann E, Osinusi AO, Wu L, Sachau W, Lempicki RA, Yang J, et al. Twice-weekly pegylated interferon- α-2a and ribavirin results in superior viral kinetics in HIV/ hepatitis C virus co-infected patients compared to standard therapy. AIDS 2011; 25(9): 1179-87.